Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 23
Filtrer
1.
Clin Nutr ; 43(3): 603-619, 2024 03.
Article de Anglais | MEDLINE | ID: mdl-38301284

RÉSUMÉ

BACKGROUND: The hypothalamus is a crucial brain region that mediates the effects of insulin and leptin signals on peripheral metabolic functions. Previous research has shown that insulin signals in the hypothalamus act via multiple neuronal circuits and anabolic/catabolic pathways that converge on the vagus nerve and sympathetic fibers to coordinate energy metabolism in peripheral organs. Additionally, neuropeptide FF (NPFF) has been identified as a regulator of feeding behaviors and energy homeostasis in the hypothalamus, but the mechanisms underlying its involvement in metabolic control remain unclear. This study aims to explore the underlying mechanisms of NPFF in modulating metabolic disorders. METHODS: In this study, we investigated the physiological role of NPFF in insulin-related energy homeostasis and metabolic health. First, we evaluated the effects of NPFF and its receptors on central insulin signaling using mouse hypothalamic cell lines and Npffr2-overexpressing mice. To further explore the effects of NPFFR2 on insulin-related metabolic disorders, such as diabetes mellitus, we used Npffr2-deleted mice in combination with the streptozotocin (STZ)-induced type 1 diabetes and high-fat diet/STZ-induced type 2 diabetic mouse models. The impacts of central NPFFR2 were demonstrated specifically through Npffr2 overexpression in the hypothalamic arcuate nucleus, which subsequently induced type 2 diabetes. RESULTS: We found that stimulating NPFFR2 in the hypothalamus blocked hypothalamic insulin activity. Npffr2 deletion improved central and peripheral metabolic symptoms in both mouse models of diabetes mellitus, exerting effects on central and systemic insulin resistance, feeding behaviors, glucose and insulin intolerance, lipid metabolism, liver steatosis, and inflammation of white adipose tissues. The overexpression of ARC Npffr2 augmented the metabolic dysregulation in the mouse model of type 2 diabetes. CONCLUSIONS: Our findings demonstrate that hypothalamic NPFFR2 negatively regulates insulin signaling in the central nervous system and plays an important role in maintaining systemic metabolic health, thereby providing valuable insights for potential clinical interventions targeting these health challenges.


Sujet(s)
Diabète de type 1 , Diabète de type 2 , Animaux , Souris , Insuline , Diabète de type 2/génétique , Hypothalamus , Homéostasie , Modèles animaux de maladie humaine
2.
Life Sci ; 328: 121900, 2023 Sep 01.
Article de Anglais | MEDLINE | ID: mdl-37391066

RÉSUMÉ

AIMS: Epidemiological evidence suggests that comorbidity of obesity and depression is extremely common and continues to grow in prevalence. However, the mechanisms connecting these two conditions are unknown. In this study, we explored how treatment with KATP channel blocker glibenclamide (GB) or the well-known metabolic regulator FGF21 impact male mice with high-fat diet (HFD)-induced obesity and depressive-like behaviors. MATERIALS AND METHODS: Mice were fed with HFD for 12 weeks and then treated with recombinant FGF21 protein by infusion for 2 weeks, followed by intraperitoneal injection of 3 mg/kg recombinant FGF21 once per day for 4 days. Measurements were made of catecholamine levels, energy expenditure, biochemical endpoints and behavior tests, including sucrose preference and forced swim tests were. Alternatively, animals were infused with GB into brown adipose tissue (BAT). The WT-1 brown adipocyte cell line was used for molecular studies. KEY FINDINGS: Compared to HFD controls, HFD + FGF21 mice exhibited less severe metabolic disorder symptoms, improved depressive-like behaviors, and more extensive mesolimbic dopamine projections. FGF21 treatment also rescued HFD-induced dysregulation of FGF21 receptors (FGFR1 and co-receptor ß-klotho) in the ventral tegmental area (VTA), and it altered dopaminergic neuron activity and morphology in HFD-fed mice. Importantly, we also found that FGF21 mRNA level and FGF21 release were increased in BAT after administration of GB, and GB treatment to BAT reversed HFD-induced dysregulation of FGF21 receptors in the VTA. SIGNIFICANCE: GB administration to BAT stimulates FGF21 production in BAT, corrects HFD-induced dysregulation of FGF21 receptor dimers in VTA dopaminergic neurons, and attenuates depression-like symptoms.


Sujet(s)
Tissu adipeux brun , Dépression , Facteurs de croissance fibroblastique , Glibenclamide , Hypoglycémiants , Obésité , Animaux , Mâle , Souris , Tissu adipeux brun/effets des médicaments et des substances chimiques , Dépression/complications , Dépression/traitement médicamenteux , Alimentation riche en graisse , Facteurs de croissance fibroblastique/administration et posologie , Facteurs de croissance fibroblastique/génétique , Glibenclamide/administration et posologie , Hypoglycémiants/administration et posologie , Maladies métaboliques/traitement médicamenteux , Souris de lignée C57BL , Neurones/effets des médicaments et des substances chimiques , Neurones/anatomopathologie , Obésité/complications , Obésité/traitement médicamenteux , Obésité/anatomopathologie , Récepteur facteur croissance fibroblaste/métabolisme , Aire tegmentale ventrale/effets des médicaments et des substances chimiques , Aire tegmentale ventrale/anatomopathologie , Protéines recombinantes/administration et posologie
3.
J Neurochem ; 165(5): 741-755, 2023 06.
Article de Anglais | MEDLINE | ID: mdl-36840377

RÉSUMÉ

Parkinson's disease (PD) is a common movement disorder caused by a characteristic loss of dopaminergic neurons in the substantia nigra and degeneration of dopamine terminals in the dorsal striatum. Previous studies have suggested that oxidative stress-induced DNA damage may be involved in PD pathogenesis, as steady-state levels of several types of oxidized nucleobases were shown to be elevated in PD brain tissues. These DNA lesions are normally removed from the genome by base excision repair, which is initiated by DNA glycosylase enzymes such as endonuclease VIII-like 1 (Neil1). In this study, we show that Neil1 plays an important role in limiting oxidative stress-induced degeneration of dopaminergic neurons. In particular, Neil1-deficient male mice exhibited enhanced sensitivity to nigrostriatal degeneration after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration, and Neil1-deficient animals had higher levels of γH2AX-marked DNA damage than wild-type (WT) controls, regardless of treatment status. Moreover, MPTP-treated Neil1-/- male mice had slightly elevated expression of genes related to the nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent antioxidant pathway. Treatment with the Nrf2 activator, monomethyl fumarate, reduced PD-like behaviors and pathology in Neil1-/- male mice, suggesting that Neil1 is an important defense molecule in an oxidative cellular environment. Taken together, these results suggest that Neil1 DNA glycosylase may play an important role in limiting oxidative stress-mediated PD pathogenesis.


Sujet(s)
DNA Glycosylases , Maladie de Parkinson , Mâle , Souris , Animaux , Maladie de Parkinson/métabolisme , 1-Méthyl-4-phényl-1,2,3,6-tétrahydropyridine/métabolisme , 1-Méthyl-4-phényl-1,2,3,6-tétrahydropyridine/pharmacologie , Deoxyribonuclease (pyrimidine dimer)/métabolisme , Neurones dopaminergiques/métabolisme , Facteur-2 apparenté à NF-E2/génétique , Facteur-2 apparenté à NF-E2/métabolisme , Substantia nigra/anatomopathologie , DNA Glycosylases/génétique , DNA Glycosylases/métabolisme , Souris de lignée C57BL , Modèles animaux de maladie humaine , Corps strié/métabolisme
4.
Pharmacol Res ; 186: 106532, 2022 12.
Article de Anglais | MEDLINE | ID: mdl-36334876

RÉSUMÉ

The stress of the abnormal stromal matrix of solid tumors is a major limiting factor that prevents drug penetration. Controlled, accurate, and efficient delivery of theranostic agents into tumor cells is crucial. Combining ultrasound with nanocarrierbased drug delivery systems have become a promising approach for targeted drug delivery in preclinical cancer therapy. In this study, to ensure effective tumor barrier penetration, access to the tumor microenvironment, and local drug release, we designed targeted nanoparticle (NP)-conjugated microbubbles (MBs); ultrasound could then help deliver acoustic energy to release the NPs from the MBs. The ultrasound-targeted MB destruction (UTMD) system of negatively charged NPs was conjugated with positively charged MBs using an ionic gelation method. We demonstrated the transfer of targeted NPs and their entry into gastric cancer cells through ligand-specific recognition, followed by enhanced cell growth inhibition owing to drug delivery-induced apoptosis. Moreover, the UTMD system combining therapeutic and ultrasound image properties can effectively target gastric cancer, thus significantly enhancing antitumor activity, as evident by tumor localization in an orthotopic mouse model of gastric cancer. The combination of ultrasound and NP-based drug delivery systems has become a promising approach for targeted drug delivery in preclinical cancer therapy.


Sujet(s)
Nanoparticules , Tumeurs de l'estomac , Souris , Animaux , Microbulles , Tumeurs de l'estomac/imagerie diagnostique , Tumeurs de l'estomac/traitement médicamenteux , Lignée cellulaire tumorale , Échographie , Systèmes de délivrance de médicaments/méthodes , Microenvironnement tumoral
5.
Biomedicines ; 10(7)2022 Jul 04.
Article de Anglais | MEDLINE | ID: mdl-35884899

RÉSUMÉ

The brain-gut-microbiome (BGM) axis affects host bioinformation. N-3 polyunsaturated fatty acids (PUFAs) alleviate cognitive impairment and depression in older adults. This study investigated altered microbiota-bile acid signalling as a potential mechanism linking fish oil-induced gut changes in microbiota to alleviate psychological symptoms. Sprague Dawley rats were fed a fish oil diet and administered D-galactose combined with chronic unpredictable mild stress (CUMS) to simulate geriatric depression. The cognitive function, psychological symptoms, microbiota compositions, and faecal bile acid profiles of the rats were assessed thereafter. A correlation analysis was conducted to determine whether the fish oil-induced alteration of the rats' microbiota and bile acid profiles affected the rats' behaviour. D-galactose and CUMS resulted in lower concentrations of Firmicutes, significantly altered bile acid profiles, and abnormal neurobehaviours. Fish oil intake alleviated the rats' emotional symptoms and increased the abundance of Bacteroidetes, Prevotellaceae, Marinifilaceae, and Bacteroidesuniformis. It also elevated the concentrations of primary bile acids and taurine-conjugated bile acids in the rats' faeces. The rats' taurine-conjugated bile acid levels were significantly correlated with their behavioural outcomes. In short, fish oil intake may alleviate psychological symptoms by altering the microbial metabolites involved in the BGM axis, especially in the conjugation of bile acids.

6.
Int J Mol Sci ; 22(14)2021 Jul 16.
Article de Anglais | MEDLINE | ID: mdl-34299230

RÉSUMÉ

The precise neural mechanisms underlying the pathogenesis of depression are largely unknown, though stress-induced brain inflammation and serotonergic plasticity are thought to be centrally involved. Moreover, we previously demonstrated that neuropeptide FF receptor 2 (NPFFR2) overexpression provokes depressive-like behaviors in mice. Here, we assess whether NPFFR2 is involved in priming of depressive-like behaviors and downregulation of serotonergic 1A receptor (5HT1AR) after lipopolysaccharide (LPS) treatment. The forced swimming test (FST) and sucrose preference test (SPT) were used to quantify depressive-like phenotypes in wild-type (WT) and NPFFR2-knockout (KO) mice. A single dose of LPS (i.p. 1 mg/kg) readily caused increases in toll-like receptor 4 and tumor necrosis factor-α along with decreases in 5-HT1AR mRNA in the ventral hippocampus of WT mice. Furthermore, LPS treatment of WT mice increased immobility time in FST and decreased sucrose preference in SPT. In contrast, none of these effects were observed in NPFFR2-KO mice. While WT mice injected with lentiviral 5-HT1AR shRNA in the ventral hippocampus displayed an unaltered response after LPS challenge, LPS-challenged NPFFR2-KO mice displayed a profound decrease in sucrose preference when pretreated with 5-HT1AR shRNA. Taken together, these results suggest that NPFFR2 modulates LPS-induced depressive-like behavioral phenotypes by downregulating 5HT1AR in the ventral hippocampus.


Sujet(s)
Dépression/génétique , Récepteur de la sérotonine de type 5-HT1A/métabolisme , Récepteur aux neuropeptides/génétique , Animaux , Comportement animal/physiologie , Dépression/métabolisme , Modèles animaux de maladie humaine , Femelle , Hippocampe/métabolisme , Lipopolysaccharides/effets indésirables , Lipopolysaccharides/pharmacologie , Souris , Souris de lignée C57BL , Souris knockout , Activité motrice/effets des médicaments et des substances chimiques , Récepteur de la sérotonine de type 5-HT1A/génétique , Récepteur aux neuropeptides/métabolisme , Récepteur de type Toll-4/métabolisme , Facteur de nécrose tumorale alpha/métabolisme
7.
J Headache Pain ; 21(1): 140, 2020 Dec 07.
Article de Anglais | MEDLINE | ID: mdl-33287697

RÉSUMÉ

An amendment to this paper has been published and can be accessed via the original article.

8.
Cells ; 9(11)2020 11 14.
Article de Anglais | MEDLINE | ID: mdl-33202667

RÉSUMÉ

Mental stress is highly related to many clinical symptoms and disorders, as it activates the hypothalamic-pituitary-adrenocortical (HPA) axis to affect a wide variety of physiological functions. Furthermore, stress leads to the aberrations in HPA axis activity and disruptions of body homeostasis. It was previously shown that neuropeptide FF (NPFF) regulates the HPA axis through the activation of hypothalamus paraventricular nucleus (PVN), and genetic overexpression or pharmacological stimulation of NPFF receptor 2 (NPFFR2) triggers hyperactivity of HPA axis and suppresses behavioral correlates of emotion in mice. In this study, we further examined the role of NPFFR2 in stress response in mice by utilizing a single prolonged stress (SPS). SPS is considered a model of post-traumatic stress disorder (PTSD), and mice undergo physical restraint, forced swimming, and ether anesthesia within a day followed by social isolation for one week. NPFFR2 knockout B6 mice were generated by CRISPR/Cas9 technology and exposed to SPS. The NPFFR2 knockouts showed resistance to stress exposure-induced anxiety-like behaviors and HPA axis hyperactivity. Additionally, the hippocampal mRNA levels of glucocorticoid receptor and mineralocorticoid receptor were reduced in wild-type (WT) mice but not in NPFFR2 knockouts after stress exposure. Our data also suggested that NPFFR2 knockout mice have stronger negative feedback on the HPA axis after exposure to SPS. Mice with intra-PVN Npffr2 shRNA injection displayed trends toward resistance to SPS exposure in both behavioral and molecular assays. Together, our findings suggest that NPFFR2 may be a potential therapeutic target for disorders relating to stress/anxiety and HPA dysregulation.


Sujet(s)
Délétion de gène , Récepteurs de surface cellulaire/métabolisme , Récepteur aux neuropeptides/métabolisme , Stress psychologique/métabolisme , Animaux , Séquence nucléotidique , Comportement animal , Modèles animaux de maladie humaine , Femelle , Régulation de l'expression des gènes , Extinction de l'expression des gènes , Axe hypothalamohypophysaire/physiopathologie , Mâle , Souris de lignée C57BL , Souris knockout , Noyau paraventriculaire de l'hypothalamus/métabolisme , Axe hypophyso-surrénalien/physiopathologie , ARN messager/génétique , ARN messager/métabolisme , Récepteurs de surface cellulaire/génétique , Récepteurs aux glucocorticoïdes/génétique , Récepteurs aux glucocorticoïdes/métabolisme , Récepteur aux neuropeptides/génétique
9.
J Headache Pain ; 21(1): 87, 2020 Jul 08.
Article de Anglais | MEDLINE | ID: mdl-32640973

RÉSUMÉ

BACKGROUND: Stimulation of trigeminovascular pathway is widely used to establish the headache animal model. Headache is a common neurological disorder, in which symptomatic attacks are mediated by calcitonin-gene-related peptide (CGRP). CGRP is synthesized and released from the trigeminal ganglion to transmit pain signals under stimulation. On the other hand, Neuropeptide FF (NPFF) is a candidate transmitter/modulator for migraine, and stimulation of its receptor, NPFFR2, increases the expression and release of CGRP in mice sensory neurons. Here, we investigate the impact of NPFFR2 on trigeminal CGRP level in a capsaicin-induced headache mouse model. METHODS: Mice were intracisternally injected with capsaicin into the cisterna magna to activate the trigeminovascular pathway and induce headache symptoms. Mice pretreated with Npffr2-shRNA or NPFFR2 knockouts were adopted to test the impact of NPFFR2 on capsaicin-induced CGRP upregulation in trigeminal ganglion. The gene silencing effect of Npffr2-shRNA in trigeminal ganglion was confirmed by real-time PCR. Trigeminal CGRP level was determined by immunofluorescence staining, and the percentage of CGRP-positive cell was calculated after setting the signal intensity threshold by Image J software. Amount of trigeminal CGRP in NPFFR2 overexpressed mice was also measured by CGRP ELISA. FINDINGS: Infusion of capsaicin into the cisterna magna upregulated the CGRP in trigeminal ganglion and induced spontaneous pain behaviors including the reduction of locomotor activity and the increase of freezing behavior. Intracisternal injection of Npffr2-shRNA reduced the mRNA of Npffr2 in trigeminal ganglion. Mice pretreatment with Npffr2-shRNA prevented capsaicin-induced CGRP upregulation in trigeminal ganglion. Similarly, CGRP upregulation was also reduced in NPFFR2 knockout mice. On the contrary, trigeminal CGRP was increased in NPFFR2 overexpressed mice. CONCLUSIONS: Reducing the level of NPFFR2 leads to the downregulation of capsaicin-induced CGRP in trigeminal ganglion, which would consequently attenuate the activation of trigeminovascular pathway. Thus, NPFFR2 could serve as a potential target for neuromodulation of cephalic pain.


Sujet(s)
Peptide relié au gène de la calcitonine/métabolisme , Capsaïcine/pharmacologie , Récepteur aux neuropeptides/métabolisme , Ganglion trigéminal/métabolisme , Animaux , Calcitonine/génétique , Modèles animaux de maladie humaine , Mâle , Souris , Souris de lignée C57BL , Migraines/métabolisme , Neurones afférents/métabolisme , Rats , Régulation positive/effets des médicaments et des substances chimiques
10.
Psychoneuroendocrinology ; 118: 104712, 2020 08.
Article de Anglais | MEDLINE | ID: mdl-32479969

RÉSUMÉ

BACKGROUND: Obesity, a critical feature in metabolic disorders, is associated with medical depression. Recent evidence reveals that brown adipose tissue (BAT) activity may contribute to mood disorders, Adenosine triphosphate (ATP)-sensitive K+ (KATP) channels regulate BAT sympathetic nerve activity. However, the mechanism through which BAT activity affects mood control remains unknown. We hypothesized the BAT is involved in depressive-like symptoms regulation by trafficking KATP channels. METHODS: Eight-week-old male B6 mice fed with a high-fat diet (HFD) for 12 weeks exhibited characteristics of metabolic disorders, including hyperglycemia, hyperinsulinemia, and hyperlipidemia, as well as depressive symptoms. In this study, we surgically removed interscapular BAT in mice, and these mice exhibited immobility in the forced swim test and less preference for sugar water compared with other mice. To delineate the role of KATP channels in BAT activity regulation, we implanted a miniosmotic pump containing glibenclamide (GB), a KATP channel blocker, into the interscapular BAT of HFD-fed mice. RESULTS: GB infusion improved glucose homeostasis, insulin sensitivity, and depressive-like symptoms. KATP channel expression was lower in HFD-fed mice than in chow-fed mice. Notably, GB infusion in HFD-fed mice restored KATP channel expression. CONCLUSION: KATP channels are functionally expressed in BAT, and inhibiting BAT-KATP channels improves metabolic syndromes and reduces depressive symptoms through beta-3-adrenergic receptor-mediated protein kinase A signaling.


Sujet(s)
Tissu adipeux brun/effets des médicaments et des substances chimiques , Neurones dopaminergiques/effets des médicaments et des substances chimiques , Glibenclamide/pharmacologie , Réseau nerveux/effets des médicaments et des substances chimiques , Obésité , Récompense , Tissu adipeux brun/innervation , Tissu adipeux brun/métabolisme , Tissu adipeux brun/physiopathologie , Animaux , Cellules cultivées , Cytoprotection/effets des médicaments et des substances chimiques , Alimentation riche en graisse , Neurones dopaminergiques/physiologie , Métabolisme énergétique/effets des médicaments et des substances chimiques , Métabolisme énergétique/physiologie , Canaux KATP/antagonistes et inhibiteurs , Canaux KATP/physiologie , Mâle , Souris , Souris de lignée C57BL , Souris obèse , Réseau nerveux/physiologie , Obésité/métabolisme , Obésité/physiopathologie , Obésité/psychologie , Système nerveux sympathique/effets des médicaments et des substances chimiques , Système nerveux sympathique/métabolisme , Thermogenèse/effets des médicaments et des substances chimiques
11.
Biochem Biophys Res Commun ; 517(1): 77-83, 2019 09 10.
Article de Anglais | MEDLINE | ID: mdl-31327496

RÉSUMÉ

Intra-neuronal α-synuclein (αSNCA) aggregation are the leading cause of dopaminergic neuron degeneration in Parkinson's disease (PD). Most PD patients is linked with αSNCA gene mutations. Gene therapy shows therapeutic potential by packing gene into viral vectors to improve gene expression through stereotactic brain injections. However, through intracranial injection, the gene expression is typically limited with tissue distribution tightly adjacent to the injection track, when expressing therapeutic genes for a wider CNS region is preferable. We use microbubble-facilitated ultrasound pulsations (MB-USP) as a new gene delivering tool to enhance the limit gene delivery of local injection in brain and evaluate the feasibility using αSNCA as model gene. We demonstrate that MB-USP can transfect naked constructs DNA of αSNCA gene into two types of neuron cells and enhance the gene expression. We confirm α-synuclein fusion protein functionality, showing that α-synuclein fusion protein significantly reduce the mitochondrial activity. We show MB-USP improves in vivo gene transfer in the brain with naked construct local injection, significantly enhances α-synuclein expression level to 1.68-fold, and broaden its distribution to 25-fold. In vivo fused α-synuclein protein aggregation is also found in gene-injected mice brains by MB-USP. MB-USP provides an alternative to α-synuclein over expression in vitro and in vivo model for investigation of α-synuclein related PD therapeutic strategies.


Sujet(s)
Techniques de transfert de gènes , Vecteurs génétiques/génétique , Maladie de Parkinson/génétique , alpha-Synucléine/génétique , Animaux , Lignée cellulaire , Thérapie génétique , Vecteurs génétiques/administration et posologie , Vecteurs génétiques/usage thérapeutique , Mâle , Souris , Souris de lignée C57BL , Microbulles , Maladie de Parkinson/thérapie , Ondes ultrasonores , Régulation positive
12.
Chin J Physiol ; 62(2): 47-52, 2019.
Article de Anglais | MEDLINE | ID: mdl-31243174

RÉSUMÉ

Neuropeptide FF (NPFF) is known as a morphine-modulating peptide and was first isolated in 1985. It has been characterized as an RF-amide peptide. The traditional role of NPFF is mediation of the pain response, and it displays both anti-opioid and pro-opioid actions through central nervous system. In the recent decade, additional evidence has revealed some untraditional features of NPFF, such as regulation of the neuroendocrine system, energy homeostasis, anti-inflammation, pain transmission, and peripheral modulation of adipose tissue macrophages. Neuropeptide FF receptor 2 (NPFFR2) is a physiological receptor of NPFF, and the actions of NPFF may occur through downstream NPFFR2 signaling. NPFF and NPFFR2 increase the neuronal activity in various areas of the hypothalamus to modulate the hypothalamic-pituitary-adrenal axis, the autonomic nervous system, food intake, and energy balance. These underlying cellular mechanisms have been explored in the past few years. Here, we review the impact of NPFF and related RF-amide peptides on hypothalamic function. The interaction of NPFF with NPFFR2 in the hypothalamus is emphasized, and NPFF-NPFFR2 system may represent an important therapeutic target in hypothalamic-related disorders in the future.


Sujet(s)
Homéostasie , Axe hypothalamohypophysaire , Hypothalamus , Système neuroendocrinien , Oligopeptides , Axe hypophyso-surrénalien , Récepteur aux neuropeptides
13.
J Vis Exp ; (140)2018 10 06.
Article de Anglais | MEDLINE | ID: mdl-30346383

RÉSUMÉ

Dorsal root ganglia (DRG) contain cell bodies of sensory neurons. This type of neuron is pseudo-unipolar, with two axons that innervate peripheral tissues, such as skin, muscle and visceral organs, as well as the spinal dorsal horn of the central nervous system. Sensory neurons transmit somatic sensation, including touch, pain, thermal, and proprioceptive sensations. Therefore, DRG primary cultures are widely used to study the cellular mechanisms of nociception, physiological functions of sensory neurons, and neural development. The cultured neurons can be applied in studies involving electrophysiology, signal transduction, neurotransmitter release, or calcium imaging. With DRG primary cultures, scientists may culture dissociated DRG neurons to monitor biochemical changes in single or multiple cells, overcoming many of the limitations associated with in vivo experiments. Compared to commercially available DRG-hybridoma cell lines or immortalized DRG neuronal cell lines, the composition and properties of the primary cells are much more similar to sensory neurons in tissue. However, due to the limited number of cultured DRG primary cells that can be isolated from a single animal, it is difficult to perform high-throughput screens for drug targeting studies. In the current article, procedures for DRG collection and culture are described. In addition, we demonstrate the treatment of cultured DRG cells with an agonist of neuropeptide FF receptor type 2 (NPFFR2) to induce the release of peptide neurotransmitters (calcitonin gene-related peptide (CRGP) and substance P (SP)).


Sujet(s)
Peptide relié au gène de la calcitonine/métabolisme , Ganglions sensitifs des nerfs spinaux/cytologie , Ganglions sensitifs des nerfs spinaux/métabolisme , Substance P/métabolisme , Animaux , Cellules cultivées , Ganglions sensitifs des nerfs spinaux/effets des médicaments et des substances chimiques , Neurogenèse/effets des médicaments et des substances chimiques , Neurogenèse/physiologie , Neuropeptides/pharmacologie , Rats , Récepteur aux neuropeptides/agonistes , Récepteur aux neuropeptides/métabolisme , Cellules réceptrices sensorielles/effets des médicaments et des substances chimiques , Cellules réceptrices sensorielles/métabolisme , Transmission synaptique/effets des médicaments et des substances chimiques , Transmission synaptique/physiologie
14.
Sci Rep ; 8(1): 12882, 2018 08 27.
Article de Anglais | MEDLINE | ID: mdl-30150769

RÉSUMÉ

Alzheimer's disease (AD) is a neurodegenerative disease that is the leading cause of age-related dementia. Currently, therapeutic agent delivery to the CNS is a valued approach for AD therapy. Unfortunately, the CNS penetration is greatly hampered by the blood-brain barrier (BBB). Focused-ultrasound (FUS) has been demonstrated to temporally open the BBB, thus promoting therapeutic agent delivery to the CNS. Recently, the BBB opening procedure was further reported to clear the deposited Aß plaque due to microglia activation. In this study, we aimed to evaluate whether the use of FUS-induced BBB opening to enhance GSK-3 inhibitor delivery, which would bring additive effect of Aß plaque clearance by FUS with the reduction of Aß plaque synthesis by GSK-3 inhibitor in an AD mice model. FUS-induced BBB opening on APPswe/PSEN1-dE9 transgenic mice was performed unilaterally, with the contralateral hemisphere serving as a reference. GSK-3 level was confirmed by immunohistochemistry (IHC) and autoradiography (ARG) was also conducted to quantitatively confirm the Aß plaque reduction. Results from IHC showed GSK-3 inhibitor effectively reduced GSK-3 activity up to 61.3% with the addition of FUS-BBB opening and confirming the proposed therapeutic route. ARG also showed significant Aß-plaque reduction up to 31.5%. This study reveals the therapeutic potentials of ultrasound to AD treatment, and may provide a useful strategy for neurodegenerative disease treatment.


Sujet(s)
Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Barrière hémato-encéphalique/effets des radiations , Antienzymes/pharmacologie , Glycogen Synthase Kinase 3/antagonistes et inhibiteurs , Glycogen Synthase Kinase 3/métabolisme , Ondes ultrasonores , Peptides bêta-amyloïdes/métabolisme , Animaux , Marqueurs biologiques , Encéphale/métabolisme , Encéphale/anatomopathologie , Immunohistochimie , Mâle , Souris , Souris transgéniques , Plaque amyloïde/métabolisme , Plaque amyloïde/anatomopathologie , Agrégats de protéines , Agrégation pathologique de protéines , Liaison aux protéines , Thiazoles/pharmacologie , Urée/analogues et dérivés , Urée/pharmacologie
15.
Int J Mol Sci ; 18(8)2017 Aug 21.
Article de Anglais | MEDLINE | ID: mdl-28825666

RÉSUMÉ

Neuropeptide FF (NPFF) belongs to the RFamide family and is known as a morphine-modulating peptide. NPFF regulates various hypothalamic functions through two receptors, NPFFR1 and NPFFR2. The hypothalamic-pituitary-adrenal (HPA) axis participates in physiological stress response by increasing circulating glucocorticoid levels and modulating emotional responses. Other RFamide peptides, including neuropeptide AF, neuropeptide SF and RFamide related peptide also target NPFFR1 or NPFFR2, and have been reported to activate the HPA axis and induce anxiety- or depression-like behaviors. However, little is known about the action of NPFF on HPA axis activity and anxiety-like behaviors, and the role of the individual receptors remains unclear. In this study, NPFFR2 agonists were used to examine the role of NPFFR2 in activating the HPA axis in rodents. Administration of NPFFR2 agonists, dNPA (intracerebroventricular, ICV) and AC-263093 (intraperitoneal, IP), time-dependently (in rats) and dose-dependently (in mice) increased serum corticosteroid levels and the effects were counteracted by the NPFF receptor antagonist, RF9 (ICV), as well as corticotropin-releasing factor (CRF) antagonist, α-helical CRF(9-41) (intravenous, IV). Treatment with NPFFR2 agonist (AC-263093, IP) increased c-Fos protein expression in the hypothalamic paraventricular nucleus and induced an anxiogenic effect, which was evaluated in mice using an elevated plus maze. These findings reveal, for the first time, that the direct action of hypothalamic NPFFR2 stimulates the HPA axis and triggers anxiety-like behaviors.


Sujet(s)
Trouble dépressif/métabolisme , Oligopeptides/métabolisme , Récepteur aux neuropeptides/métabolisme , Hormones corticosurrénaliennes/sang , Animaux , Anxiété , Corticolibérine/administration et posologie , Corticolibérine/antagonistes et inhibiteurs , Trouble dépressif/sang , Trouble dépressif/physiopathologie , Hydrazines/administration et posologie , Axe hypothalamohypophysaire/métabolisme , Axe hypothalamohypophysaire/physiopathologie , Hypothalamus/métabolisme , Hypothalamus/anatomopathologie , Souris , Oligopeptides/administration et posologie , Fragments peptidiques/administration et posologie , Rats , Récepteur aux neuropeptides/agonistes
17.
J Clin Invest ; 127(7): 2842-2854, 2017 Jun 30.
Article de Anglais | MEDLINE | ID: mdl-28581443

RÉSUMÉ

The quantity and activation state of adipose tissue macrophages (ATMs) impact the development of obesity-induced metabolic diseases. Appetite-controlling hormones play key roles in obesity; however, our understanding of their effects on ATMs is limited. Here, we have shown that human and mouse ATMs express NPFFR2, a receptor for the appetite-reducing neuropeptide FF (NPFF), and that NPFFR2 expression is upregulated by IL-4, an M2-polarizing cytokine. Plasma levels of NPFF decreased in obese patients and high-fat diet-fed mice and increased following caloric restriction. NPFF promoted M2 activation and increased the proliferation of murine and human ATMs. Both M2 activation and increased ATM proliferation were abolished in NPFFR2-deficient ATMs. Mechanistically, the effects of NPFF involved the suppression of E3 ubiquitin ligase RNF128 expression, resulting in enhanced stability of phosphorylated STAT6 and increased transcription of the M2 macrophage-associated genes IL-4 receptor α (Il4ra), arginase 1 (Arg1), IL-10 (Il10), and alkylglycerol monooxygenase (Agmo). NPFF induced ATM proliferation concomitantly with the increase in N-Myc downstream-regulated gene 2 (Ndrg2) expression and suppressed the transcription of Ifi200 cell-cycle inhibitor family members and MAF bZIP transcription factor B (Mafb), a negative regulator of macrophage proliferation. NPFF thus plays an important role in supporting healthy adipose tissue via the maintenance of metabolically beneficial ATMs.


Sujet(s)
Tissu adipeux/immunologie , Prolifération cellulaire , Activation des macrophages , Macrophages/immunologie , Oligopeptides/immunologie , Protéines adaptatrices de la transduction du signal , Animaux , Arginase/génétique , Arginase/immunologie , Interleukine-10/génétique , Interleukine-10/immunologie , Interleukine-4/génétique , Interleukine-4/immunologie , Facteur de transcription MafB/génétique , Facteur de transcription MafB/immunologie , Mâle , Souris , Souris transgéniques , Oligopeptides/génétique , Protéines/génétique , Protéines/immunologie , Récepteurs de surface cellulaire/génétique , Récepteurs de surface cellulaire/immunologie , Ubiquitin-protein ligases/génétique , Ubiquitin-protein ligases/immunologie
18.
Exp Neurol ; 291: 62-73, 2017 05.
Article de Anglais | MEDLINE | ID: mdl-28179153

RÉSUMÉ

Neuropeptide FF (NPFF) is recognized as an opioid modulating peptide that regulates morphine-induced analgesia. The aim of this study was to delineate the role of NPFFR2 in pain transmission. We found the expression levels of NPFF and NPFFR2 were increased in the lumbar dorsal horn of animals with CFA- and carrageenan-induced inflammation and both NPFFR2 over-expressing transgenic (NPFFR2-Tg) and NPFFR2 agonist-treated mice displayed hyperalgesia. BOLD signals from functional MRI showed that NPFFR2-Tg mice exhibited increased activation of pain-related brain regions after painful stimulation when compared to WT mice. Inflammatory mediators within the spinal cord, calcitonin gene-related peptide (CGRP) and substance P (SP), were up-regulated in NPFFR2-Tg and chronic NPFFR2 agonist-treated mice. In DRG cultures, treatment with an NPFFR2 agonist induced the expression and release of CGRP, an action which was blocked by NPFFR2 siRNA. Furthermore, treatment with a CGRP antagonist ameliorated the pain hyperalgesia in NPFFR2-Tg mice, returning the pain threshold to a control level. However, treatment with a SP antagonist reduced the pain responses in both WT and NPFFR2-Tg mice and did not suppress pain hypersensitivity in NPFFR2-Tg mice. Together, these results demonstrate that NPFFR2 activation modulates pain transmission by up-regulating the pain mediator CGRP, leading to hyperalgesia.


Sujet(s)
Peptide relié au gène de la calcitonine/métabolisme , Régulation de l'expression des gènes/génétique , Hyperalgésie/étiologie , Hyperalgésie/métabolisme , Myélite/complications , Récepteurs couplés aux protéines G/métabolisme , Animaux , Carragénane/toxicité , Cellules cultivées , Cortex cérébral/imagerie diagnostique , Modèles animaux de maladie humaine , Membre thoracique/innervation , Adjuvant Freund/toxicité , Ganglions sensitifs des nerfs spinaux/cytologie , Hydrazines/pharmacologie , Mâle , Souris , Souris de lignée C57BL , Souris transgéniques , Myélite/induit chimiquement , Neurones/effets des médicaments et des substances chimiques , Neurones/métabolisme , Agents neuromédiateurs/métabolisme , Oxygène/sang , Mesure de la douleur , Récepteurs couplés aux protéines G/génétique , Facteurs temps
19.
Psychoneuroendocrinology ; 71: 73-85, 2016 09.
Article de Anglais | MEDLINE | ID: mdl-27243477

RÉSUMÉ

Neuropeptide FF (NPFF) is a morphine-modulating peptide that regulates the analgesic effect of opioids, and also controls food consumption and cardiovascular function through its interaction with two cognate receptors, NPFFR1 and NPFFR2. In the present study, we explore a novel modulatory role for NPFF-NPFFR2 in stress-related depressive behaviors. In a mouse model of chronic mild stress (CMS)-induced depression, the expression of NPFF significantly increased in the hypothalamus, hippocampus, medial prefrontal cortex (mPFC) and amygdala. In addition, transgenic (Tg) mice over-expressing NPFFR2 displayed clear depression and anxiety-like behaviors with hyperactivity in the hypothalamic-pituitary-adrenal (HPA) axis, reduced expression of glucocorticoid receptor (GR) and neurogenesis in the hippocampus. Furthermore, acute treatment of NPFFR2 agonists in wild-type (WT) mice enhanced the activity of the HPA axis, and chronic administration resulted in depressive and anxiety-like behaviors. Chronic stimulation of NPFFR2 also decreased the expression of hippocampal GR and led to persistent activation of the HPA axis. Strikingly, bilateral intra-paraventricular nucleus (PVN) injection of NPFFR2 shRNA predominately inhibits the depressive-like behavior in CMS-exposed mice. Antidepressants, fluoxetine and ketamine, effectively relieved the depressive behaviors of NPFFR2-Tg mice. We speculate that persistent NPFFR2 activation, in particular in the hypothalamus, up-regulates the HPA axis and results in long-lasting increases in circulating corticosterone (CORT), consequently damaging hippocampal function. This novel role of NPFFR2 in regulating the HPA axis and hippocampal function provides a new avenue for combating depression and anxiety-like disorder.


Sujet(s)
Dépression/physiopathologie , Récepteur aux neuropeptides/métabolisme , Animaux , Antidépresseurs/pharmacologie , Anxiété , Troubles anxieux/métabolisme , Maladie chronique/psychologie , Corticostérone/métabolisme , Corticolibérine/métabolisme , Trouble dépressif/physiopathologie , Expression des gènes , Hippocampe/métabolisme , Axe hypothalamohypophysaire/effets des médicaments et des substances chimiques , Axe hypothalamohypophysaire/métabolisme , Axe hypothalamohypophysaire/physiopathologie , Hypothalamus/métabolisme , Mâle , Souris , Souris de lignée C57BL , Souris transgéniques , Modèles animaux , Axe hypophyso-surrénalien/effets des médicaments et des substances chimiques , Axe hypophyso-surrénalien/métabolisme , Axe hypophyso-surrénalien/physiopathologie , Cortex préfrontal/métabolisme , Récepteurs aux glucocorticoïdes/métabolisme , Récepteur aux neuropeptides/physiologie , Stress physiologique/effets des médicaments et des substances chimiques , Stress psychologique/métabolisme
20.
PLoS One ; 8(2): e57682, 2013.
Article de Anglais | MEDLINE | ID: mdl-23460893

RÉSUMÉ

Recombinant adeno-associated viral (rAAV) vectors are potentially powerful tools for gene therapy of CNS diseases, but their penetration into brain parenchyma is severely limited by the blood-brain barrier (BBB) and current delivery relies on invasive stereotactic injection. Here we evaluate the local, targeted delivery of rAAV vectors into the brains of mice by noninvasive, reversible, microbubble-facilitated focused ultrasound (FUS), resulting in BBB opening that can be monitored and controlled by magnetic resonance imaging (MRI). Using this method, we found that IV-administered AAV2-GFP (green fluorescence protein) with a low viral vector titer (1×10(9) vg/g) can successfully penetrate the BBB-opened brain regions to express GFP. We show that MRI monitoring of BBB-opening could serve as an indicator of the scale and distribution of AAV transduction. Transduction peaked at 3 weeks and neurons and astrocytes were affected. This novel, noninvasive delivery approach could significantly broaden the application of AAV-viral-vector-based genes for treatment of CNS diseases.


Sujet(s)
Encéphale/métabolisme , Techniques de transfert de gènes , Microbulles , Science des ultrasons/méthodes , Animaux , Astrocytes/métabolisme , Barrière hémato-encéphalique/métabolisme , Technique de Western , Produits de contraste , Dependovirus/génétique , Technique d'immunofluorescence , Vecteurs génétiques/génétique , Protéines à fluorescence verte/métabolisme , Imagerie par résonance magnétique , Mâle , Souris , Souris de lignée ICR , Reproductibilité des résultats , Transduction génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...